The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review.
Mansour TobaiqyNawal HelmiKathrine MaclureSylvia SaadePublished in: International journal of clinical pharmacy (2023)
High frequency of mild and severe hepatotoxicity, associated with imatinib in CML patients, was reported in the published literature. Low numbers of mild and manageable thyroid toxicity events were reported.
Keyphrases
- high frequency
- chronic myeloid leukemia
- transcranial magnetic stimulation
- end stage renal disease
- oxidative stress
- ejection fraction
- newly diagnosed
- chronic kidney disease
- systematic review
- drug induced
- risk factors
- prognostic factors
- early onset
- acute myeloid leukemia
- randomized controlled trial
- oxide nanoparticles